In near future, given the dual action both on striatum and immune surveillance, we propose that the gene transfer or alternatively the usage of a human recombinant protein of LAV-BPIFB4 in presymptomatic HD carriers may represent a promising strategy to improve HD symptoms or delay its onset. Here, BPIFB4 is linked to Huntington disease.